Bristol Myers Squibb announces Opdivo Plus Yervoy (ipilimumab) improved overall survival for patients with unresectable hepatocellular carcinoma

Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population

AstraZeneca’s Tagrisso plus chemo recommended for approval in EU

Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months

Sun Pharma to present results of the Phase III PIVOTAL trial of Nidlegy in melanoma at ASCO 2024

PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy

Ascentage releases results from multiple clinical studies of its lead drug candidates

These abstracts report on the company's three lead drug candidates, including olverembatinib

Ascentage Pharma releases latest results from multiple clinical studies of lead drug candidates

Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting

AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore

Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs

Glenmark and BeiGene ink agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India

IIHMR Start-ups inks MoU with BMCHRC & HCG Hospital

The collaboration aims to bolster healthcare entrepreneurship

LVPEI raises awareness and funds for retinoblastoma treatment with WHITATHON Run

The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma

Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19

SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients